Related Experiment Video
Updated: Aug 3, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Current and future treatment of hepatitis C
M P Manns1, M Cornberg, H Wedemeyer
1Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Hannover, Germany. manns.michael@mh-hannover.de
Hepatitis C virus (HCV) treatments have evolved from limited interferon-alpha success to improved response rates with pegylated interferons and ribavirin. Future therapies aim to further suppress HCV replication.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) infection poses a significant global health challenge, leading to cirrhosis and end-stage liver disease.
- Interferon-alpha monotherapy offers limited success (10-15%) for sustained virological response in chronic hepatitis C.
- Combination therapy with interferon-alpha and ribavirin improves response rates to 40%.
Purpose of the Study:
- To review the evolution of Hepatitis C virus treatments.
- To highlight advancements in interferon-based therapies for chronic hepatitis C.
- To discuss emerging therapeutic targets and approaches for HCV infection.
Main Methods:
- Review of clinical trials and treatment strategies for chronic hepatitis C.
- Analysis of sustained virological response rates with different therapeutic regimens.
- Exploration of novel treatment modalities and targets for HCV.
Main Results:
- Pegylated interferons combined with ribavirin achieve sustained response rates of approximately 50% with good safety.
- Modifications like induction dosing and longer-acting interferons enhance treatment efficacy.
- Potential targets for suppressing HCV replication include helicase, protease, and RNA polymerase.
Conclusions:
- Combination therapy with pegylated interferons and ribavirin represents a significant improvement in treating chronic hepatitis C.
- Ongoing research into new interferons and immunotherapeutic approaches holds promise for future HCV treatment.
- Targeting viral proteins offers a promising strategy for developing novel anti-HCV therapies.
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Retrovirus Life Cycles
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction